Literature DB >> 7543576

Shared care between general practitioners and urologists in the management of benign prostatic hyperplasia: a survey of attitudes among clinicians.

R S Kirby1, G Chisholm, C Chapple, C Hudd, M Swallow, D Shore.   

Abstract

Recent community-based population surveys have revealed a much greater prevalence of benign prostatic hyperplasia than previously suspected. From these data it has been projected that there may be more than 2 million men in the UK whose quality of life is to some extent impaired by this disorder. Since there are only 330 fully trained urologists in this country it will not be feasible for every individual presenting with prostatism to be assessed by a specialist. In an attempt to provide a more rational basis from which family practitioners can decide whether or not to refer a patient for a specialist opinion a 'shared care' flow diagram was developed and assumptions contained within field tested by means of a postal questionnaire which was sent to 2020 urologists, family practitioners and other interested clinicians. There was general agreement with most of the precepts set out in the flow diagram, the main exception was a rejection of the suggestion that every patient with prostatism should have a prostate-specific antigen level determined before referral. We conclude that there seems a consensus among respondents that a shared care approach to the management of BPH may both improve the standard of care provided in this area by family practitioners and allow hard pressed urologists to focus greater attention on those patients whose conditions require surgical expertise to resolve.

Entities:  

Mesh:

Year:  1995        PMID: 7543576      PMCID: PMC1295206     

Source DB:  PubMed          Journal:  J R Soc Med        ISSN: 0141-0768            Impact factor:   5.344


  16 in total

1.  The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association.

Authors:  M J Barry; F J Fowler; M P O'Leary; R C Bruskewitz; H L Holtgrewe; W K Mebust; A T Cockett
Journal:  J Urol       Date:  1992-11       Impact factor: 7.450

2.  Rectal examination in general practice.

Authors:  T W Hennigan; P J Franks; D B Hocken; T G Allen-Mersh
Journal:  BMJ       Date:  1990-09-08

3.  High prevalence of benign prostatic hypertrophy in the community.

Authors:  W M Garraway; G N Collins; R J Lee
Journal:  Lancet       Date:  1991-08-24       Impact factor: 79.321

Review 4.  Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate.

Authors:  J E Oesterling
Journal:  J Urol       Date:  1991-05       Impact factor: 7.450

5.  Measurement of prostate-specific antigen in serum as a screening test for prostate cancer.

Authors:  W J Catalona; D S Smith; T L Ratliff; K M Dodds; D E Coplen; J J Yuan; J A Petros; G L Andriole
Journal:  N Engl J Med       Date:  1991-04-25       Impact factor: 91.245

6.  Terazosin in the treatment of benign prostatic hyperplasia. Terazosin Benign Prostatic Hyperplasia Study Group.

Authors:  M K Brawer; G Adams; H Epstein
Journal:  Arch Fam Med       Date:  1993-09

7.  Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease.

Authors:  H B Carter; J D Pearson; E J Metter; L J Brant; D W Chan; R Andres; J L Fozard; P C Walsh
Journal:  JAMA       Date:  1992 Apr 22-29       Impact factor: 56.272

8.  The clinical effects of a 5 alpha-reductase inhibitor, finasteride, on benign prostatic hyperplasia. The Finasteride Study Group.

Authors:  E Stoner
Journal:  J Urol       Date:  1992-05       Impact factor: 7.450

9.  Large, organ confined, impalpable transition zone prostate cancer: association with metastatic levels of prostate specific antigen.

Authors:  T A Stamey; D D Dietrick; M M Issa
Journal:  J Urol       Date:  1993-03       Impact factor: 7.450

10.  The development of human benign prostatic hyperplasia with age.

Authors:  S J Berry; D S Coffey; P C Walsh; L L Ewing
Journal:  J Urol       Date:  1984-09       Impact factor: 7.450

View more
  2 in total

1.  Diagnosis and management of benign prostatic hyperplasia in primary care.

Authors:  Simon Tanguay; Murray Awde; Gerald Brock; Richard Casey; Joseph Kozak; Jay Lee; J Curtis Nickel; Fred Saad
Journal:  Can Urol Assoc J       Date:  2009-06       Impact factor: 1.862

Review 2.  Prostate specific antigen testing policy worldwide varies greatly and seems not to be in accordance with guidelines: a systematic review.

Authors:  Saskia Van der Meer; Sabine A M Löwik; Willem H Hirdes; Rien M Nijman; Klaas Van der Meer; Josette E H M Hoekstra-Weebers; Marco H Blanker
Journal:  BMC Fam Pract       Date:  2012-10-11       Impact factor: 2.497

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.